Central retinal artery occlusion was the most common cause of vision loss. Conclusion There are several risk factors for poor visual outcome after excision of OCVMs. Surgical and anaesthetic teams ...

The following is a summary of “Associations between a healthy lifestyle score and retinal neurovascular health,” published in ...

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

Injection 8 mg for treating macular edema due to retinal vein occlusion (RVO). This includes patients with central, branch, and hemiretinal vein occlusions. The data from this trial will support a ...

Our brain and eyes can play tricks on us—not least when it comes to the expanding hole illusion. A new computational model ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...

Rights Mar 17, 2011 Mar 18, 2011 Jul 29, 2010 Rights ratio: 3 share for every 5 held at a price of Rs 103.0 ...